Please login to the form below

Not currently logged in
Email:
Password:

Medius Deal Watch table for March 2015

The top major pharma mergers, acquisitions and collaborations during the month were dominated by AbbVie's Pharmacyclics mega-merger

The highest value deals in March were again dominated by company acquisitions but only one mega merger, Abbvie's acquisition of Pharmacyclics.

The price of $21bn was regarded by many commentators as very high and there were accusations that Abbvie had overpaid - but the reason for this was not the share price premium. [Read the month's pharma deal commentary in full.]

Here Medius present a run down of the month's biggest mergers, acquisitions and collaborations from across the sector.

Licensor/Licensee Acquired / Acquirer
Deal type*
Product/Technology
Headline $m
Pharmacyclics / Abbvie
Company acquisition
Marketed BTK inhibitor for haematological cancers + pipeline incl. 3 products in clinic
21,000
Auspex / Teva
Company acquisition
Phase 3 product for Huntington's Chorea + deuterium technology platform
3,500
Ikaria / Mallinckrodt
Company acquisition
Marketed critical care treatments incl. respiratory for neonatals
2,300
Cordis (J&J) / Cardinal Health
Company acquisition
J&J divest subsidiary marketing vascular devices
1,944
Covis / Concordia
Asset acquisition
18 marketed brands and generics in US acquired by Canadian company
1,200
Hyperion / Horizon
Company acquisition
2 marketed urea cycle disorder orphan drugs in the US
1,100
Bavarian Nordic / BMS
Option to license and commercialise
Phase 3 immuno-oncology treatment for prostate cancer
975
Intrexon / Merck Serono
Licence and collaboration + option
CAR-T immuno-oncology platform for identifying and developing target molecules
941
AstraZeneca / Daiichi Sankyo
Co-commercialisation US 
Marketed Movantik (naloxegol) for opioid induced constipation
825
Aduro / Novartis
Licence and collaboration
Preclinical cancer immunotherapies targeting the STING (Stimulator of Interferon Genes) pathway
750
Hanmi / Eli Lilly
Licence and collaboration**
Phase 1 BTK inhibitor for treatment of lupus
690
Innovent / Eli Lilly
Strategic alliance
Development and commercialisation with Chinese company 3 preclinical oncology drugs†
456+
Zogenix / Pernix
Acquisition product
US marketed hydrocodone (Zohydro ER) for treatment of pain
384
Cellular Dynamics / Fujiflim
Company acquisition
US-based developer and manufacturer of human cells
307
Blueprint / Alexion
Strategic collaboration China and rest of world
Kinase inhibitor platform for discovery of molecules for treatment of rare diseases
265
Immunogen / Takeda
Licence and collaboration + option
Antibody-drug conjugate (ADC) technology to develop 2 anticancer products + option on 3rd
230
SuppreMol / Baxter
Company acquisition
Biologic immuno-regulatory pipeline with phase 2 lead product for treatment of ITP and lupus
225
Athersys / Chugai
Licence and collaboration Japan
Phase 2 stem cell therapy for treatment of ischaemic stroke
205
Alkermes / Recro
Asset acquisition
Purchase of US factory and associated products and pipeline
170
Checkpoint Therapeutics / TG
Licence and collaboration
Human anti-PD-L1 and anti-GITR antibody preclinical programmes for  haematological cancers
165
Brighthaven Ventures/ Islet Sciences
Licence and collaboration***
Phase 2b SGLT2 inhibitor remogliflozin for treatment of diabetes
117
Sorrento / Nantcell
Licence and collaboration
Discovery and development of anticancer products incl. CAR-T and checkpoint inhibitors PD-1 and PD-L1
110
Transtech / Calithera
Licence and collaboration
Portfolio of hexokinase II inhibitors for treatment of cancer
109
Astellas / Vical
Licence and collaboration
Preclinical antifungal ASP2397
100

* Licence and collaboration means exclusive global rights to develop and commercialise unless otherwise stated

** Global rights excluding China, Hong Kong, Taiwan and Korea

*** Global rights excluding Latin America, China, Korea, Taiwan and Japan

† Innovent to receive a total upfront payment of $56m and potential milestones of over $400m for one of the molecules, a preclinical immuno-oncology molecule. 

The Deal Watch table is compiled by Medius Associates

13th May 2015

From: Research, Sales

Share

Tags


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

Established in 2002, Star is a full service outsourcing and resourcing company that works with the best people and opportunities...

Infographics